Epigenome Frontiers — Biology, Disease and Therapeutics is a peer-reviewed, open-access journal dedicated to advancing our understanding of the epigenome — the dynamic regulatory layer that shapes gene expression, cellular identity, development, aging, and disease. The journal provides a scholarly forum for research that spans the full continuum from fundamental chromatin biology to clinical translation, therapeutic development, and the emerging science of longevity and healthspan extension. The epigenome sits at the interface of genetics and environment, integrating developmental cues, metabolic signals, stress responses, and lifestyle exposures into stable yet reversible patterns of gene regulation. Understanding how these patterns are established, maintained, disrupted, and potentially restored is one of the most compelling frontiers in modern biomedical science, and Epigenome Frontiers exists to publish rigorous, interdisciplinary research that illuminates this frontier and accelerates its translation into clinical and societal benefit.
The journal welcomes contributions across the following thematic areas: Molecular and Cellular Epigenome Biology, including chromatin structure, dynamics, and nuclear architecture; DNA methylation, hydroxymethylation, and demethylation; histone modifications, variants, and chromatin remodeling; non-coding RNAs and epitranscriptomics; epigenome maintenance, inheritance, and reprogramming; and single-cell and spatial epigenomics.
Aging, Longevity, and Healthspan encompasses epigenetic mechanisms of aging and cellular senescence; epigenetic clocks and biological age estimation; longevity interventions and anti-aging strategies; partial reprogramming, rejuvenation, and regenerative epigenetics; caloric restriction, exercise, and lifestyle effects on the epigenome; and comparative and evolutionary epigenetics of aging.
Disease Mechanisms and Pathophysiology covers cancer epigenetics and epigenomic instability; neuroepigenetics and neurodegenerative disease; immunoepigenetics, autoimmunity, and inflammation; metabolic, cardiovascular, and pulmonary epigenetics; developmental and imprinting disorders; environmental epigenetics and exposomics; and transgenerational epigenetic inheritance.
Therapeutic Development and Clinical Translation addresses epigenetic drugs (DNMT inhibitors, HDAC inhibitors, BET inhibitors, etc.); epigenome editing and targeted gene regulation; pharmacoepigenomics and personalized medicine; clinical trials and biomarker development; combination therapies and resistance mechanisms; and safety, off-target effects, and ethical considerations.
Computational, Theoretical, and Integrative Approaches includes computational and systems epigenomics; machine learning and AI in epigenome analysis; multi-omics integration and network biology; theoretical models of epigenetic regulation and aging; and methodological advances in epigenome research.
The journal publishes Original Research Articles presenting novel empirical, experimental, computational, or clinical research; Review Articles offering critical and integrative syntheses of established or emerging fields; Theoretical and Conceptual Articles proposing new frameworks, models, and interpretations; Hypothesis and Theory Articles presenting scientifically grounded propositions for further investigation; Methods and Methodological Articles introducing new or substantially improved research methods; Perspectives providing forward-looking discussions of emerging developments and unresolved questions; Commentaries offering focused scholarly discussion of important issues; Short Communications presenting concise reports of significant findings; and Letters to the Editor providing constructive commentary on published work.
The journal does not assume that epigenetic interventions necessarily represent unqualified progress. Epigenetic reprogramming, rejuvenation strategies, and longevity interventions may produce new therapeutic capabilities and health benefits, but they may also produce unintended consequences, off-target effects, oncogenic risks, identity concerns, equity issues, or other unresolved challenges. Research addressing these possibilities is welcomed when supported by rigorous scientific reasoning or empirical evidence. Epigenome Frontiers seeks to provide a rigorous scientific forum for investigating how the epigenome shapes health, disease, aging, and the future of human medicine:
From Chromatin to Clinic.
From Mechanisms to Therapeutics.
From Biology to Healthspan.
